Literature DB >> 15806416

Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers.

S Neri1, C M Bruno, D Pulvirenti, M Malaguarnera, C Italiano, B Mauceri, G Abate, D Cilio, S Calvagno, A Tsami, L Ignaccolo, D Interlandi, L Prestianni, M Ricchena, R Noto.   

Abstract

RATIONALE: Buprenorphine may be a useful alternative option to methadone in addicts. Opioids can produce severe changes in the immune system.
OBJECTIVES: The objectives of this study are to compare the effect of sublingual buprenorphine and methadone on the immune system and to compare the two substances on the drying-out program compliance.
METHODS: We studied 62 randomized outpatients for a period of 12 months. Subjects (55 males and 7 females; mean age 25+/-4 years; average history of heroin abuse being 2 years) on maintenance treatment were assigned in two groups (A and B). Methadone chloride (medium dose 100 mg/day) was administered to group A, whereas group B received sublingual buprenorphine (32.40+/-2.8 mg/day). Urine toxicological screening, plasma levels of TNF-alpha interleukin-1, interleukin-beta, lymphocyte CD14 and a self-rating depression questionnaire were measured.
RESULTS: Urine screening was negative for opiates in 17.6% of group A and in 10.7% of group B (p<0.001; r = 0.62). Depression score was 62+/-2 in group A and 55+/-3 in group B (p < 0.01). Cytokine and CD14 revealed higher concentrations both in groups A and B without significant differences (p > 0.05) between the two groups.
CONCLUSIONS: The effects of buprenorphine and methadone tested on the immune system were overlapping in our patients. The elevated cytokine levels observed may suggest that the two drugs stimulate immunologic hyperactivation of an immune system that was formerly inhibited by heroin. Furthermore, our data suggest that buprenorphine can be a valid alternative to methadone in maintenance treatment of chronic heroin abuse and referred a marked decline in depression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806416     DOI: 10.1007/s00213-005-2239-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Injecting misuse of buprenorphine among French drug users.

Authors:  Y Obadia; V Perrin; I Feroni; D Vlahov; J P Moatti
Journal:  Addiction       Date:  2001-02       Impact factor: 6.526

2.  Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France.

Authors:  Gwenaëlle Vidal-Trecan; Isabelle Varescon; Norbert Nabet; Alain Boissonnas
Journal:  Drug Alcohol Depend       Date:  2003-03-01       Impact factor: 4.492

3.  Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b.

Authors:  Sergio Neri; Cosimo M Bruno; Giuseppe Abate; Dario Ierna; Barbara Mauceri; Danila Cilio; Fabio Bordonaro; Davide Pulvirenti; Claudio Italiano; Luciano Caruso
Journal:  Clin Ther       Date:  2002-10       Impact factor: 3.393

4.  Tolerance development to morphine-induced alterations of immune status.

Authors:  J P West; D T Lysle; L A Dykstra
Journal:  Drug Alcohol Depend       Date:  1997-07-04       Impact factor: 4.492

5.  A flow cytometric immune function assay for human peripheral blood dendritic cells.

Authors:  K Willmann; J F Dunne
Journal:  J Leukoc Biol       Date:  2000-04       Impact factor: 4.962

Review 6.  Pharmacologic treatment of heroin-dependent patients.

Authors:  P G O'Connor; D A Fiellin
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

Review 7.  Mechanisms of morphine-induced immunomodulation.

Authors:  P K Peterson; T W Molitor; C C Chao
Journal:  Biochem Pharmacol       Date:  1993-08-03       Impact factor: 5.858

8.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

9.  Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment.

Authors:  H V Curran; J Bolton; S Wanigaratne; C Smyth
Journal:  Addiction       Date:  1999-05       Impact factor: 6.526

10.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more
  21 in total

Review 1.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

2.  Black spotted larynx, a finding in patients addicted to inhalational opium.

Authors:  Ehsan Khadivi; Kianoosh Nahid; Reza Afshari; Reza Ziaolhagh
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-01       Impact factor: 2.503

3.  Decreased spinal cord opioid receptor mRNA expression and antinociception in a Theiler's murine encephalomyelitis virus model of multiple sclerosis.

Authors:  Jessica L Lynch; Jeremy F Alley; Lori Wellman; Alvin J Beitz
Journal:  Brain Res       Date:  2007-11-28       Impact factor: 3.252

4.  Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.

Authors:  Albert Stuart Reece
Journal:  Subst Abuse       Date:  2012-09-27

Review 5.  The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV.

Authors:  Corrilynn O Hileman; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.495

6.  Heroin use is associated with suppressed pro-inflammatory cytokine response after LPS exposure in HIV-infected individuals.

Authors:  Hinta Meijerink; Agnes Indrati; Fitri Utami; Suharyani Soedarmo; Bachti Alisjahbana; Mihai G Netea; Reinout van Crevel; Rudi Wisaksana; Andre Jam van der Ven
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

7.  The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales.

Authors:  Dave Marteau; Rebecca McDonald; Kamlesh Patel
Journal:  BMJ Open       Date:  2015-05-29       Impact factor: 2.692

Review 8.  Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria.

Authors:  Brittany B Dennis; Pavel S Roshanov; Leen Naji; Monica Bawor; James Paul; Carolyn Plater; Guillaume Pare; Andrew Worster; Michael Varenbut; Jeff Daiter; David C Marsh; Dipika Desai; Zainab Samaan; Lehana Thabane
Journal:  Trials       Date:  2015-10-21       Impact factor: 2.279

Review 9.  Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.

Authors:  Brittany B Dennis; Monica Bawor; Leen Naji; Carol K Chan; Jaymie Varenbut; James Paul; Michael Varenbut; Jeff Daiter; Carolyn Plater; Guillaume Pare; David C Marsh; Andrew Worster; Dipika Desai; Lehana Thabane; Zainab Samaan
Journal:  Subst Abuse       Date:  2015-09-10

10.  Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women.

Authors:  Albert Stuart Reece; Gary Kenneth Hulse
Journal:  BMJ Open       Date:  2014-06-02       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.